Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.

@article{OSullivan2009DecreasedBT,
  title={Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.},
  author={Susannah O'Sullivan and Anne M. Horne and Diana J. Wattie and Fran Porteous and Karen E. Callon and Greg Gamble and Peter R. Ebeling and Peter J Browett and Andrew Grey},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2009},
  volume={94 4},
  pages={
          1131-6
        }
}
CONTEXT The tyrosine kinase inhibitor imatinib mesylate has an established role in the management of a number of malignant and proliferative conditions. Cross-sectional and short-term prospective studies have demonstrated secondary hyperparathyroidism during imatinib therapy, and variable changes in markers of bone turnover. OBJECTIVE Our objective was to determine the biochemical and skeletal effects of imatinib during long-term therapy. DESIGN This was a 2-yr prospective study. SETTING… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ

VIEW 7 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS

Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.

Ellin Berman, Monica Girotra, +7 authors Azeez Farooki
  • Leukemia research
  • 2013
VIEW 9 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment

  • Medical science monitor : international medical journal of experimental and clinical research
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

The safety profile of imatinib in CML and GIST: long-term considerations

  • Archives of Toxicology
  • 2011
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED